Fibroblast growth factor 23 is associated with a frequent exacerbator phenotype in COPD

A cross-sectional pilot study

Swati Gulati, J. Michael Wells, Gisel P. Urdaneta, Kira Balestrini, Isabel Vital, Katherine Tovar, Jarrod W. Barnes, Surya P. Bhatt, Michael A Campos, Stefanie Krick

Research output: Contribution to journalArticle

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory airway disease punctuated by exacerbations (AECOPD). Subjects with frequent AECOPD, defined by having at least two exacerbations per year, experience accelerated loss of lung function, deterioration in quality of life and increase in mortality. Fibroblast growth factor (FGF)23, a hormone associated with systemic inflammation and altered metabolism is elevated in COPD. However, associations between FGF23 and AECOPD are unknown. In this cross-sectional study, individuals with COPD were enrolled between June 2016 and December 2016. Plasma samples were analyzed for intact FGF23 levels. Logistic regression analyses were used to measure associations between clinical variables, FGF23, and the frequent exacerbator phenotype. Our results showed that FGF23 levels were higher in frequent exacerbators as compared to patients without frequent exacerbations. FGF23 was also independently associated with frequent exacerbations (OR 1.02; 95%CI 1.004–1.04; p = 0.017), after adjusting for age, lung function, smoking, and oxygen use. In summary, FGF23 was associated with the frequent exacerbator phenotype and correlated with number of exacerbations recorded retrospectively and prospectively. Further studies are needed to explore the role of FGF 23 as a possible biomarker for AECOPD to better understand the pathobiology of COPD and to help develop therapeutic targets.

Original languageEnglish (US)
Article number2292
JournalInternational journal of molecular sciences
Volume20
Issue number9
DOIs
StatePublished - May 1 2019

Fingerprint

Pulmonary diseases
phenotype
fibroblasts
Fibroblasts
Chronic Obstructive Pulmonary Disease
Cross-Sectional Studies
Phenotype
lungs
Lung
Hormones
Biomarkers
Metabolism
hormones
mortality
biomarkers
Deterioration
logistics
Disease Progression
Logistics
metabolism

Keywords

  • COPD
  • FGF23
  • Inflammation

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Fibroblast growth factor 23 is associated with a frequent exacerbator phenotype in COPD : A cross-sectional pilot study. / Gulati, Swati; Wells, J. Michael; Urdaneta, Gisel P.; Balestrini, Kira; Vital, Isabel; Tovar, Katherine; Barnes, Jarrod W.; Bhatt, Surya P.; Campos, Michael A; Krick, Stefanie.

In: International journal of molecular sciences, Vol. 20, No. 9, 2292, 01.05.2019.

Research output: Contribution to journalArticle

Gulati, Swati ; Wells, J. Michael ; Urdaneta, Gisel P. ; Balestrini, Kira ; Vital, Isabel ; Tovar, Katherine ; Barnes, Jarrod W. ; Bhatt, Surya P. ; Campos, Michael A ; Krick, Stefanie. / Fibroblast growth factor 23 is associated with a frequent exacerbator phenotype in COPD : A cross-sectional pilot study. In: International journal of molecular sciences. 2019 ; Vol. 20, No. 9.
@article{38ab389dca6f45b59c102f765b8e8cb3,
title = "Fibroblast growth factor 23 is associated with a frequent exacerbator phenotype in COPD: A cross-sectional pilot study",
abstract = "Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory airway disease punctuated by exacerbations (AECOPD). Subjects with frequent AECOPD, defined by having at least two exacerbations per year, experience accelerated loss of lung function, deterioration in quality of life and increase in mortality. Fibroblast growth factor (FGF)23, a hormone associated with systemic inflammation and altered metabolism is elevated in COPD. However, associations between FGF23 and AECOPD are unknown. In this cross-sectional study, individuals with COPD were enrolled between June 2016 and December 2016. Plasma samples were analyzed for intact FGF23 levels. Logistic regression analyses were used to measure associations between clinical variables, FGF23, and the frequent exacerbator phenotype. Our results showed that FGF23 levels were higher in frequent exacerbators as compared to patients without frequent exacerbations. FGF23 was also independently associated with frequent exacerbations (OR 1.02; 95{\%}CI 1.004–1.04; p = 0.017), after adjusting for age, lung function, smoking, and oxygen use. In summary, FGF23 was associated with the frequent exacerbator phenotype and correlated with number of exacerbations recorded retrospectively and prospectively. Further studies are needed to explore the role of FGF 23 as a possible biomarker for AECOPD to better understand the pathobiology of COPD and to help develop therapeutic targets.",
keywords = "COPD, FGF23, Inflammation",
author = "Swati Gulati and Wells, {J. Michael} and Urdaneta, {Gisel P.} and Kira Balestrini and Isabel Vital and Katherine Tovar and Barnes, {Jarrod W.} and Bhatt, {Surya P.} and Campos, {Michael A} and Stefanie Krick",
year = "2019",
month = "5",
day = "1",
doi = "10.3390/ijms20092292",
language = "English (US)",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

TY - JOUR

T1 - Fibroblast growth factor 23 is associated with a frequent exacerbator phenotype in COPD

T2 - A cross-sectional pilot study

AU - Gulati, Swati

AU - Wells, J. Michael

AU - Urdaneta, Gisel P.

AU - Balestrini, Kira

AU - Vital, Isabel

AU - Tovar, Katherine

AU - Barnes, Jarrod W.

AU - Bhatt, Surya P.

AU - Campos, Michael A

AU - Krick, Stefanie

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory airway disease punctuated by exacerbations (AECOPD). Subjects with frequent AECOPD, defined by having at least two exacerbations per year, experience accelerated loss of lung function, deterioration in quality of life and increase in mortality. Fibroblast growth factor (FGF)23, a hormone associated with systemic inflammation and altered metabolism is elevated in COPD. However, associations between FGF23 and AECOPD are unknown. In this cross-sectional study, individuals with COPD were enrolled between June 2016 and December 2016. Plasma samples were analyzed for intact FGF23 levels. Logistic regression analyses were used to measure associations between clinical variables, FGF23, and the frequent exacerbator phenotype. Our results showed that FGF23 levels were higher in frequent exacerbators as compared to patients without frequent exacerbations. FGF23 was also independently associated with frequent exacerbations (OR 1.02; 95%CI 1.004–1.04; p = 0.017), after adjusting for age, lung function, smoking, and oxygen use. In summary, FGF23 was associated with the frequent exacerbator phenotype and correlated with number of exacerbations recorded retrospectively and prospectively. Further studies are needed to explore the role of FGF 23 as a possible biomarker for AECOPD to better understand the pathobiology of COPD and to help develop therapeutic targets.

AB - Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory airway disease punctuated by exacerbations (AECOPD). Subjects with frequent AECOPD, defined by having at least two exacerbations per year, experience accelerated loss of lung function, deterioration in quality of life and increase in mortality. Fibroblast growth factor (FGF)23, a hormone associated with systemic inflammation and altered metabolism is elevated in COPD. However, associations between FGF23 and AECOPD are unknown. In this cross-sectional study, individuals with COPD were enrolled between June 2016 and December 2016. Plasma samples were analyzed for intact FGF23 levels. Logistic regression analyses were used to measure associations between clinical variables, FGF23, and the frequent exacerbator phenotype. Our results showed that FGF23 levels were higher in frequent exacerbators as compared to patients without frequent exacerbations. FGF23 was also independently associated with frequent exacerbations (OR 1.02; 95%CI 1.004–1.04; p = 0.017), after adjusting for age, lung function, smoking, and oxygen use. In summary, FGF23 was associated with the frequent exacerbator phenotype and correlated with number of exacerbations recorded retrospectively and prospectively. Further studies are needed to explore the role of FGF 23 as a possible biomarker for AECOPD to better understand the pathobiology of COPD and to help develop therapeutic targets.

KW - COPD

KW - FGF23

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=85065941820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065941820&partnerID=8YFLogxK

U2 - 10.3390/ijms20092292

DO - 10.3390/ijms20092292

M3 - Article

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 9

M1 - 2292

ER -